Spain’s largest drugmaker Almirall (ALM: MC) has announced the closing of a $15 million in Series C equity investment in privately-held US firm Suneva Medical, an innovative aesthetics leader that markets Bellafill.
This product is the only dermal filler on the market that is US Food and Drug Administration-approved proven to be safe and effective for the correction of moderate to severe, atrophic, distensible facial acne scars on the cheek, in patients over the age of 21 years, according to the Spanish company. The deal will give Almirall a position on the Suneva board of directors as Suneva continues with its plans to be active in prescription, aesthetics and medicalized OTC Dermatology.
Eduardo Sanchiz, chief executive of Almirall, commented: "We are very pleased to confirm this strategic investment in Suneva Medical. Almirall is looking for attractive business development opportunities in the dermatology field and this actually represents our first investment in the aesthetics area. We were attracted by the quality of Suneva´s portfolio and management team and this partnership will allow us to further build our understanding of the aesthetics dermatology market in the US."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze